By Adam Bonislawski
Bio-Rad has developed a workflow linking surface plasmon resonance to MALDI mass spectrometry that could offer a more sensitive and streamlined alternative to conventional SPR-MS techniques.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Calling Affymetrix a "turnaround story," investment firm Mizuho Securities initiated coverage of the microarray firm with an Outperform rating and a price target of $6 per share.
Participants are calling the Human Microbiome Project a second Human Genome Project. The massive global effort aims to get to the bottom of the relationship between microorganism and host, and disease and health.